UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DELAWARE 94-3120386 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share STXS NYSE American LLC FORM 10-Q (MARK ONE) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐TRANSITIO ...

Exhibit 99.1 Stereotaxis Reports 2024 Third Quarter Financial Results St. Louis, Nov. 11, 2024 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said ...

Financial Data and Key Metrics - Revenue for Q3 2024 totaled $9.2 million, an 18% YoY increase compared to $7.8 million in Q3 2023 [22] - System revenue was $4.4 million, driven by partial revenue recognition from the delivery of three Genesis systems, compared to $3.5 million in Q3 2023 [22] - Recurring revenue was $4.8 million, up from $4.3 million in Q3 2023, reflecting the two-month contribution from the APT acquisition [23] - Gross margin for Q3 2024 was 45%, with recurring revenue gross margin at 70% and system gross margin at 16% [24] - Operating loss and net loss for Q3 2024 were $6.3 million and $6.2 million, respectively, compared to $5.6 million and $5.4 million in Q3 2023 [26] - Adjusted operating loss and adjusted net loss, excluding non-cash charges, were $3.1 million and $3 million, respectively [27] - Negative free cash flow for Q3 2024 was $4.2 million [27] - Cash and cash equivalents, including restricted cash, stood at $11 million at the end of September 2024, increasing to $13.3 million by the end of October 2024 [28] Business Line Data and Key Metrics - Revenue growth in Q3 2024 was driven by the partial revenue recognition of three Genesis systems delivered to European hospitals [6] - The company received orders for two additional Genesis systems in Q3, leaving a capital backlog of $15.5 million at the end of the quarter [7] - The APT acquisition contributed approximately $0.5 million in catheter revenue in Q3, with expectations for larger contributions in Q4 [10] - The company is advancing regulatory approvals for the MAGiC catheter, high-density mapping catheter, and vascular guidance catheter, with submissions expected in early 2025 [15][55] Market Data and Key Metrics - Europe remains the strongest market for the company, with the most advanced product ecosystem and regulatory approvals [9] - The U.S. and China are slightly behind Europe in terms of regulatory approvals, but the company expects these regions to increasingly contribute to capital orders and revenue [9] - The company is working with MicroPort in China to gain regulatory approval for the Genesis robot, mapping integration, and a novel ablation catheter [20] Company Strategy and Industry Competition - The company is focused on building a comprehensive product ecosystem, including the Genesis X system, MAGiC catheter, and vascular guidance devices, to drive growth and adoption [8][15] - The acquisition of APT is seen as a strategic move to enhance the company's product portfolio and recurring revenue streams [10][11] - The company is investing in innovation and regulatory efforts to expand its presence in the electrophysiology and broader endovascular markets [4][18] Management Commentary on Operating Environment and Future Outlook - Management is optimistic about the near-term approval of the MAGiC catheter in Europe and expects significant commercial adoption [12][13] - The company is maintaining its revenue guidance for 2024, expecting year-over-year growth in both system and recurring revenue in upcoming quarters [29] - Management is focused on protecting the balance sheet and managing expenses prudently while investing in growth opportunities [30][31] Other Important Information - The company is preparing for the regulatory submission of the high-density mapping catheter and vascular guidance catheter in early 2025 [15][55] - The company is also advancing preclinical studies for robotic PFA programs, with potential first-in-human studies expected in 2025 [63][64] Q&A Session Summary Question: Timeline for MAGiC catheter approval in Europe and the U.S. [33] - Management expects CE Mark approval for MAGiC in Europe in the very short term, with U.S. approval likely in the next couple of quarters [34][35] Question: Market dynamics in the U.S. and Europe [36] - Europe's advanced product ecosystem is driving strong commercial results, while the U.S. and China are catching up [39][41] Question: APT catheter portfolio and revenue growth expectations [47] - The APT catheter portfolio is seeing positive reception, with expectations for meaningful sequential revenue growth in Q4 and beyond [51][52] Question: Robotic HD mapping catheter and recurring revenue per case [54] - Regulatory submissions for the high-density mapping catheter and vascular guidance catheter are expected in early 2025, with potential to significantly increase recurring revenue per procedure [55][56] Question: MAGiC catheter supply and sales force [59] - The company is confident in its ability to supply the market with MAGiC and is preparing to expand its sales force in Europe [60][61] Question: PFA program updates [62] - The company is advancing two robotic PFA programs, with potential first-in-human studies in 2025 [63][64] Question: Guidewire and guide catheter development [66] - The guide catheter is expected to be submitted for regulatory approval in Q1 2025, while the guidewire development is progressing more slowly [67][68]

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -60%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.07, delivering a surprise of -75%. Over the last four quarters, the company has surpassed ...

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. “The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline,” said David Fischel, Chairman and CEO. “We are making broad, methodical pro ...

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN ...

ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will represent Stereotaxis at two upcoming investor conferences. H.C. Wainwright 26th Annual Global Investment Conference Mr. Fischel will present an overview of Stereotaxis business on Wednesday, September 11th, 2024, at 12:30 pm EST and will be available that same day for one-on-one m ...

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society (HRS), is focused on exploring digital technologies that advance the boundaries of innovation in cardiovascular me ...

eternalcreative/iStock via Getty Images Initial Takeaways From Q2 Report: GenesisX Submissions/Approval & MAGiC Making Progress Heading into the Q2 earnings report, I was most concerned about the GenesisX submission timeline. Stereotaxis (NYSE:STXS) management originally projected the robot would be submitted to regulators in late 2022. That guidance was way too aggressive. Then, in mid to late 2023, the firm suggested the robot was nearly ready for regulatory submission, but the company wanted to wait unti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share STXS NYSE American LLC FORM 10-Q (MARK ONE) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FIL ...